

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. 056291-5230	APPLICATION NO 10/565,100	
				APPLICANT BATEMAN et al.		
				FILING DATE January 19, 2006	GROUP to be assigned	
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DD	A01 6,287,599	09/2001	Burnside et al			
DD	A02 5,641,536	06/1997	Lech et al.			
	A03					
	A04					
	A05					
	A06					
	A07					
	A08					
	A09					

**FOREIGN PATENT DOCUMENTS**


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
B01							
B02							
B03							
B04							
B05							

EXAMINER *Patricia Dulce*

DATE CONSIDERED 2/19/2005

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE</b> (Use several sheets if necessary)			Attorney Docket No. 056291-5230-US	Application No. 10/565,100		
			Applicants: Nicola F. BATEMAN <i>et al.</i>			
			Filing Date: January 19, 2006		Group Art Unit: <i>Unassigned</i>	
<b>U.S. PATENT DOCUMENTS</b>						
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
17	20020009494	January 24, 2002	Curatolo et al.	424	489	January 26, 2001
	20020177601	November 28, 2002	Himmelsbach et al.	514	266.2	August 23, 2001
	20030045537	March 6, 2003	Lee et al.	514	267	March 11, 2002
	20050209229	September 22, 2005	Gilday et al.	514	234.2	May 23, 2005
	3,608,063	September 21, 1971	Banker	424	485	August 15, 1969
	4,178,376	December 11, 1979	Higuchi et al.	514	311	January 21, 1977
	4,344,934	August 17, 1982	Martin et al.	514	462	February 21, 1980
	4,704,284	November 3, 1987	Beatty et al.	424	469	August 12, 1982
	5,457,105	October 10, 1995	Barker	514	234.5	August 2, 1994
	5,559,158	September 24, 1996	Al-Razzak et al.	514	616	August 31, 1994
	5,610,193	March 11, 1997	Al-Razzak et al.	514	616	May 22, 1996
	5,616,582	April 1, 1997	Barker	514	234.5	June 15, 1995
	5,631,248	May 20, 1997	Davis et al.	514	179	October 7, 1994
	6,248,771	June 19, 2001	Shenoy et al.	514	418	March 4, 1998
	6,294,192	September 25, 2001	Patel et al.	424	451	February 26, 1999
	6,383,471	May 7, 2002	Chen et al.	424	45	April 6, 1999
<b>FOREIGN PATENT DOCUMENTS</b>						
	Document No.	Date	Country	Class	Sub-Class	Translation
17.	DE 3233764	May 7, 1987	Germany			Yes
18.	EP 103387	March 21, 1984	EPA			
19.	EP 640341	March 1, 1995	EPA			
20.	EP 901786	March 17, 1999	EPA			
21.	EP 1027886	August 16, 2000	EPA			
22.	EP 1027887	August 16, 2000	EPA			
23.	EP 1027888	August 16, 2000	EPA			
24.	GB 1278816	June 21, 1972	Great Britain			
25.	GB 2306885	May 14, 1997	Great Britain			
26.	JP 05-255066	October 5, 1993	Japan			Yes
27.	JP 09-059159	March 4, 1997	Japan			Yes
28.	JP 62-123117	June 4, 1987	Japan			Yes
29.	WO 95/09614	April 13, 1995	WIPO			
30.	WO 96/33980	October 31, 1996	WIPO			
31.	WO 96/38131	December 5, 1996	WIPO			
32.	WO 97/02017	January 23, 1997	WIPO			
33.	WO 98/38984	September 11, 1998	WIPO			
34.	WO 98/55148	December 10, 1998	WIPO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>						
Examiner	<i>Paul L. Dui</i>	Date Considered	<i>2/19/2008</i>			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)			Attorney Docket No. <b>056291-5230-US</b>	Application No. <b>10/565,100</b>			
			Applicants: <b>Nicola F. BATEMAN et al.</b>				
<b>PTO Form 1449</b> August 4, 2006			Filing Date: <b>January 19, 2006</b>		Group Art Unit: <b>Unassigned</b>		
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Class	Sub-Class	Translation
DD	35.	WO 00/00179	January 6, 2000	WIPO			
	36.	WO 00/16776	March 30, 2000	WIPO			Yes
	37.	WO 00/55141	September 21, 2000	WIPO			
	38.	WO 00/56338	September 28, 2000	WIPO			
	39.	WO 00/59475	October 12, 2000	WIPO			
	40.	WO 01/04102	January 18, 2001	WIPO			
	41.	WO 01/47495	July 5, 2001	WIPO			
	42.	WO 01/76586	October 18, 2001	WIPO			
	43.	WO 02/02534	January 10, 2002	WIPO			
	44.	WO 02/06834	January 24, 2002	WIPO			
	45.	WO 02/20020	March 14, 2002	WIPO			
	46.	WO 02/64132	August 22, 2002	WIPO			
	47.	WO 02/65834	August 29, 2002	WIPO			
	48.	WO 02/89773	November 14, 2002	WIPO			
	49.	WO 03/00294	January 3, 2003	WIPO			
	50.	WO 03/017940	March 6, 2003	WIPO			
	51.	WO 03/024426	March 27, 2003	WIPO			
	52.	WO 03/024429	March 27, 2003	WIPO			
	53.	WO 03/024430	March 27, 2003	WIPO			
	54.	WO 03/032956	April 24, 2003	WIPO			
	55.	WO 03/072139	September 4, 2003	WIPO			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	56.	Barker et al. "Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" Bioorg Med Chem Lett. 11(14): 1911-1914 (2001)					
	57.	Baselga et al. "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types" J Clin Oncol. 20(21): 4292-4302 (2002)					
	58.	Berger et al. "Supersaturation of sulfates in electrodialysis" Ind. Eng. Chem., Process Design Develop. 1: 229-236 (1962) Abstract					
	59.	Brewster et al. "A Novel Cyclodextrin-containing Glass Thermoplastic System (GTS) for Formulating Poorly Water Soluble Drug Candidates: Preclinical and Clinical Results" Journal of Inclusion Phenomena and Macrocyclic Chemistry 44(1-4): 35-38 (2002)					
DD	60.	Capello et al. "Percutaneous penetration of Ibuprofen from supersaturated solutions" Acta Technologica et Legis Medicamenti XIII(1): 25-35 (2002) (Translation enclosed)					
Examiner			Date Considered	2/19/2008			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			Attorney Docket No. 056291-5230-US		Application No. 10/565,100		
			Applicants: Nicola F. BATEMAN <i>et al.</i>				
PTO Form 1449 August 4, 2006			Filing Date: January 19, 2006			Group Art Unit: Unassigned	
<b>U.S. PATENT DOCUMENTS</b>							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
<b>FOREIGN PATENT DOCUMENTS</b>							
	Document No.	Date	Country	Class	Sub-Class	Translation	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
PP	61.	Espinoza "Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets" Int J Pharm. 201(2):165-173 (2000)					
	62.	Hasegawa et al. "Supersaturation mechanism of drugs from solid dispersions with enteric coating agents" Chem Pharm Bull (Tokyo) 36(12): 4941-4950 (1988)					
	63.	Herbst et al. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial" J Clin Oncol 20(18): 3815-3825 (2002)					
	64.	Iervolino et al. "Membrane penetration enhancement of ibuprofen using supersaturation" Int. J. Pharm. 198: 229-238 (2000)					
	65.	Iervolino et al. "Penetration enhancement of ibuprofen from supersaturated solutions through human skin" Int. J. Pharm. 212: 131-141 (2001)					
	66.	Ikeda et al. "Effect of hydrophobically-modified hydroxypropyl methylcellulose on the crystallization from supersaturated solutions of indomethacin" Chem. Pharm. Bull. 42(11): 2320-2326 (1994)					
	67.	Lawrence et al. "Small-molecule tyrosine kinase inhibitors as radiosensitizers" Seminars in Radiation Oncology 12(3): 33-36 (2002)					
	68.	Loftsson et al. "The effect of water-soluble polymers on aqueous solubility of drugs" Int. J. Pharm. 127: 293-296 (1996)					
	69.	McKillop et al. "Cytochrome P450-dependent metabolism of gefitinib" Xenobiotica 35(1): 39-50 (2005)					
	70.	McKillop et al. "Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man" Xenobiotica 34(10): 917-934 (2004)					
	71.	Megrab et al. "Oestradiol permeation through human skin and silastic membrane: effects of propylene glycol and supersaturation" J. Control Rel 36: 277-294 (1995)					
	72.	Moser et al. "Stabilization of supersaturated solutions of a lipophilic drug for dermal delivery" Int. J. Pharm. 224: 169-176 (2001)					
	73.	Munday "Film coated pellets containing verapamil hydrochloride: enhanced dissolution into neutral medium" Drug Development and Industrial Pharmacy 29(5): 575-583 (2003)					
	74.	N Magné et al. "Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer" British Journal of Cancer 86: 819-827 (2002)					
	75.	Nakagawa et al. "Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors" Ann Oncol. 14(6): 922-930 (2003)					
PD	76.	Neiman et al. "Separation of a highly dispersed fraction in supersaturated solutions during formation of calcium sulfate precipitates" Kolloid. Zh. 35(4): 781-783 (1973) Abstract					
PD	77.	Pellett et al. "The penetration of supersaturated solutions of piroxicam across silicone membranes and human skin in vitro" J. Control Release 46: 205-214 (1997)					
Examiner	<i>Paul L. Davis</i>		Date Considered		<i>2/1/2007</i>		
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.